Answer
Neratinib maleate (Nerlynx) irreversibly inhibits EGFR (ERBB1), HER2 (ERBB2), and HER4 (ERBB4), or their active heterodimers with HER3 (ERBB3), through covalent, high-affinity binding to their ATP-binding sites.
Sources for this answer
- Nerlynx 40 mg film-coated tabletsPierre Fabre Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 14Document updated
Sources checked